Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy
Ocugen, Inc. has taken a significant step forward in the fight against geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), a leading cause ... Read More
Ocugen gets FDA nod to begin OCU400 clinical trial in retinitis pigmentosa
Ocugen said that the US Food and Drug Administration (FDA) has accepted its investigational new drug application (IND) to launch a first-in-human clinical trial of ... Read More